Core Viewpoint - ImmunityBio (IBRX) shares have increased by 41.1% in the past four weeks, closing at $5.01, with a mean price target of $14.25 suggesting a potential upside of 184.4% [1] Price Targets - The average price target consists of three estimates ranging from a low of $4.75 to a high of $30, with a standard deviation of $13.74, indicating variability among analysts [2] - The lowest estimate suggests a decline of 5.2%, while the highest indicates a potential upside of 498.8% [2] Analyst Sentiment - Analysts show strong agreement on IBRX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.9%, with one estimate moving higher and no negative revisions [10] Zacks Rank - IBRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [11] Earnings Estimate Revisions - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, suggesting that the positive revisions could lead to stock price increases [9]

Group 1 - Schubert Jonckheer & Kolbe LLP is investigating potential legal claims related to ImmunityBio, Inc.'s unsuccessful efforts to secure regulatory approval for its product Anktiva, which is intended for bladder cancer treatment [1] - A class action complaint has been filed against ImmunityBio, alleging that the company misled investors about the prospects of obtaining FDA approval for Anktiva by concealing issues related to recordkeeping, quality control, and sanitation at its contract manufacturer [2] - Following the revelation of these issues in May 2023, ImmunityBio's stock experienced a significant decline of 55% [2] Group 2 - The Schubert firm is looking into potential wrongdoing by ImmunityBio's officers and directors in connection with the allegations made in the class action complaint [3] - Current shareholders of ImmunityBio are encouraged to seek additional information regarding their legal rights [3]

ImmunityBio (IBRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.17 per share when it actually produced a loss of $0.20, delivering a surprise of -17.65%.Over the last four quarters, the company h ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on June 30, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company. Immunit ...

ImmunityBio (IBRX) shares soared 26.4% in the last trading session to close at $5.32. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.Last week, the company announced the dosing of the first patient in a phase I study evaluating its CAR-NK cell therapy, CD19 t-haNK, for treating relapsed B-cell non-Hodgkin lymphoma. This might have driven the share price rally.This immunotherapy company is expecte ...

Core Insights - ImmunityBio (NASDAQ: IBRX) is focusing on the commercial launch of ANKTIVA (N-803) for treating BCG-unresponsive non-muscle invasive bladder cancer, indicating a strategic positioning for rapid growth in the healthcare sector [2]. Group 1 - The company is leveraging data analytics, technical analysis, and clinical data to manage a diverse portfolio of potential multi-bagger investments in healthcare [1]. - The investment group Compounding Healthcare offers several model healthcare portfolios, a weekly newsletter, a daily watchlist, and a platform for dialogue and questions among investors [2]. - The focus of the investment strategy is on innovative companies that are developing breakthrough therapies and pharmaceuticals, particularly those with catalysts for potential acquisitions [2].

ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.65%. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.16 per share when it actually produced a loss of $0.20, delivering a surprise of -25%. Over the last four quarters, the company h ...

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX), focusing on possible self-dealing that may entitle shareholders to damages and corporate governance reforms [1]. Group 1 - The investigation by Kuehn Law concerns whether ImmunityBio's management acted in the best interests of shareholders [1]. - Shareholders may have the right to seek damages and demand changes in corporate governance practices as a result of the investigation [1]. - The law firm emphasizes the importance of shareholder participation in maintaining the integrity of financial markets [4]. Group 2 - Kuehn Law offers free consultations and covers all case costs for shareholders who wish to participate in the investigation [3]. - Shareholders are encouraged to contact Kuehn Law promptly due to potential time limitations on enforcing their rights [3]. - The firm highlights that shareholder involvement is crucial for ensuring fairness in the financial markets [4].

Core Insights - ImmunityBio's Anktiva received FDA approval in April 2024 for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) [1][8] - The approval is based on significant safety and efficacy results from a late-stage study involving 77 NMIBC CIS patients [8] - Anktiva's unique mechanism of action activates natural killer (NK) and killer T cells, providing a robust immune response against BCG-resistant tumor cells [9] Company Performance - Year to date, ImmunityBio's shares have increased by 44.8%, significantly outperforming the industry, which saw a decline of 4.1% [2] - Following the announcement of insurance coverage for Anktiva, the company's shares gained 16.7% in the past week, enhancing patient access to the drug [16] Clinical Study Results - The study reported a complete response rate of 62%, with the duration of complete response (DOR) exceeding 47 months as of November 2023 [17] - Patients in the study were treated for up to 37 months, with ongoing monitoring for up to five years [3] Product Administration and Supply - Anktiva can be administered by urologists in their offices without special handling, increasing accessibility for patients [18] - ImmunityBio has enough drug substance to produce 170,000 doses of Anktiva, ensuring preparedness for anticipated demand [19] Future Prospects - Initial sales figures for Anktiva combined with BCG are expected to be reported in the second-quarter earnings release in July or August [7] - The company is evaluating Anktiva for other cancer indications and HIV in separate clinical studies [11]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37507 _____________________________________ IMMUNITYBIO, INC. (Exact name of registrant as specified in its c ...